{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:17:17Z","timestamp":1792441037323,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10620-020-06264-9","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T08:04:02Z","timestamp":1587629042000},"page":"965-982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Mast Cell Activation Syndrome: A Primer for the Gastroenterologist"],"prefix":"10.1007","volume":"66","author":[{"given":"Leonard B.","family":"Weinstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rezaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Afrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard J.","family":"Molderings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"6264_CR1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","volume":"128","author":"MJ Hamilton","year":"2011","unstructured":"Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128:147-152","journal-title":"J Allergy Clin Immunol."},{"key":"6264_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","volume":"353","author":"LB Afrin","year":"2017","unstructured":"Afrin LB, Self S, Menk J, et al. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353:207-215.","journal-title":"Am J Med Sci."},{"key":"6264_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2018.04.002","volume":"38","author":"MJ Hamilton","year":"2018","unstructured":"Hamilton MJ. Nonclonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018;38:469-481.","journal-title":"Immunol Allergy Clin North Am."},{"key":"6264_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.iac.2018.04.008","volume":"38","author":"FH Hsieh","year":"2018","unstructured":"Hsieh FH. Gastrointestinal involvement in mast cell activation disorders. Immunol Allergy Clin North Am. 2018;38:429-441.","journal-title":"Immunol Allergy Clin North Am."},{"key":"6264_CR5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0029-1245707","volume":"49","author":"T Frieling","year":"2011","unstructured":"Frieling T, Meis K, Kolck UW, et al. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol. 2011;49:191-194.","journal-title":"Z Gastroenterol."},{"key":"6264_CR6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","volume":"48","author":"LB Afrin","year":"2016","unstructured":"Afrin LB, Butterfield JH, Raithel M, et al. Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options. Ann Med. 2016;48:190-201.","journal-title":"Ann Med."},{"key":"6264_CR7","doi-asserted-by":"publisher","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","volume":"8","author":"GJ Molderings","year":"2013","unstructured":"Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, N\u00f6then MM.\u00a0Familial Occurrence of Systemic Mast Cell Activation Disease. PLoS One. 2013;8:e76241. doi: 10.1371\/journal.pone.0076241.","journal-title":"PLoS One."},{"key":"6264_CR8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jpsychores.2008.02.021","volume":"64","author":"A Riedl","year":"2008","unstructured":"Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, M\u00f6nnikes H. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res. 2008;64:573-582.","journal-title":"J Psychosom Res."},{"key":"6264_CR9","doi-asserted-by":"publisher","first-page":"e0153911","DOI":"10.1371\/journal.pone.0153911","volume":"11","author":"TC Shen","year":"2016","unstructured":"Shen TC, Lin CL, Wei CC, et al. Bidirectional Association between Asthma and Irritable Bowel Syndrome: Two Population-Based Retrospective Cohort Studies. PLoS One. 2016;11:e0153911. doi: 10.1371\/journal.pone.0153911.eCollection 2016.","journal-title":"PLoS One."},{"key":"6264_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-230X-6-26","volume":"6","author":"JA Cole","year":"2006","unstructured":"Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol. 2006;6:26. DOI: 10.1186\/1471-230X-6-26","journal-title":"BMC Gastroenterol."},{"key":"6264_CR11","doi-asserted-by":"publisher","first-page":"e13013","DOI":"10.1111\/nmo.13013","volume":"29","author":"AB Beckers","year":"2017","unstructured":"Beckers AB, Keszthelyi D, Fikree A, et al. Gastrointestinal disorders in joint hypermobility syndrome\/Ehlers\u2010Danlos syndrome hypermobility type: A review for the gastroenterologist. Neurogastroenterol Motil. 2017;29:e13013. doi: 10.1111\/nmo.13013.","journal-title":"Neurogastroenterol Motil."},{"key":"6264_CR12","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41395-018-0215-4","volume":"113","author":"JK DiBaise","year":"2018","unstructured":"DiBaise JK, Harris LA, Goodman B. Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol. 2018;113:1458-1467.","journal-title":"Am J Gastroenterol."},{"key":"6264_CR13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajmg.c.31555","volume":"175","author":"SL Seneviratne","year":"2017","unstructured":"Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175:226-236.","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"6264_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2014.03.002","volume":"340","author":"D Wallman","year":"2014","unstructured":"Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurolog Sci. 2014;340:99-102.","journal-title":"J Neurolog Sci."},{"key":"6264_CR15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000158259.68614.40","volume":"45","author":"C Shibao","year":"2005","unstructured":"Shibao C, Arzubiaga C, Roberts LJ II, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385-390.","journal-title":"Hypertension."},{"key":"6264_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11910-015-0583-8","volume":"15","author":"EM Garland","year":"2015","unstructured":"Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15:60. doi: 10.1007\/s11910-015-0583-8.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"6264_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.autneu.2018.05.001","volume":"215","author":"TA Doherty","year":"2018","unstructured":"Doherty TA, White AA. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. 2018;215:83-88.","journal-title":"Auton Neurosci."},{"key":"6264_CR18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","volume":"2","author":"S Jennings","year":"2014","unstructured":"Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2:70-76.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"6264_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjms.2019.03.005","volume":"357","author":"JR Schofield","year":"2019","unstructured":"Schofield JR, Afrin LB. Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome. Am J Med Sci. 2019;357:507-511.","journal-title":"Am J Med Sci."},{"key":"6264_CR20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.clinthera.2015.02.008","volume":"37","author":"LB Afrin","year":"2015","unstructured":"Afrin LB, Khoruts A. Mast Cell Activation Disease and Microbiotic Interactions. Clin Ther. 2015;37:941-953.","journal-title":"Clin Ther."},{"key":"6264_CR21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.clinthera.2018.05.004","volume":"40","author":"AM Ratnaseelan","year":"2018","unstructured":"Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clin Ther. 2018;40:903-917.","journal-title":"Clin Ther."},{"key":"6264_CR22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41395-018-0257-7","volume":"113","author":"LB Weinstock","year":"2018","unstructured":"Weinstock LB, Rezaie A, Afrin LB. The significance of mast cell activation in the era of precision medicine. Am J Gastroenterol. 2018;113:1725-1726.","journal-title":"Am J Gastroenterol."},{"key":"6264_CR23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7:1125-1133.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"6264_CR24","unstructured":"Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: A global \u201cconsensus-2.\u201d Diagnosis. 2020; In press."},{"key":"6264_CR25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2019.1596800","volume":"15","author":"TC Theoharides","year":"2019","unstructured":"Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation \u2013 or should it be mast cell mediator disorders? Expert Review Clin Immunol. 2019;15:639-656.","journal-title":"Expert Rev Clin Immunol."},{"key":"6264_CR26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","volume":"121","author":"S Georgin-Lavialle","year":"2013","unstructured":"Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al. Mast cell leukemia. Blood. 2013;121:1285-1295.","journal-title":"Blood."},{"key":"6264_CR27","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.12688\/f1000research.12730.1","volume":"6","author":"GJ Molderings","year":"2017","unstructured":"Molderings GJ, Zienkiewicz T, Homann J, et al. Risk of solid cancer in patients with mast cell activation syndrome: results from Germany and USA. F1000Res. 2017;6:1889. doi: 10.12688\/f1000research.12730.1.","journal-title":"F1000Res."},{"key":"6264_CR28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1369\/0022155414545334","volume":"62","author":"EZM da Silva","year":"2014","unstructured":"da Silva EZM, Jamur MC, et al. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62:698-738.","journal-title":"J Histochem Cytochem."},{"key":"6264_CR29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2174\/1566524054863915","volume":"5","author":"H Vliagoftis","year":"2005","unstructured":"Vliagoftis H, Befus AD. Mast cells at mucosal frontiers. Curr Mol Med. 2005:573-589.","journal-title":"Curr Mol Med."},{"key":"6264_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020135","author":"M Albert-Bayo","year":"2019","unstructured":"Albert-Bayo M et al. Intestinal Mucosal Mast cell: Key modulators barrier function and homeostasis. Cells. 2019;doi: 10.3390\/cells8020135.","journal-title":"Cells."},{"key":"6264_CR31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2016.07.002","volume":"177","author":"A Rizzi","year":"2016","unstructured":"Rizzi A, Crivellato E, Benagiano V, et al. Mast cells in human digestive tube in normal and pathological conditions. Immunol Lett. 2016;177:16-21.","journal-title":"Immunol Lett."},{"key":"6264_CR32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/stem.523","volume":"28","author":"S Poglio","year":"2010","unstructured":"Poglio S, De Toni Costes F, Arnaud E, et al. Adipose tissue as a dedicated reservoir of functional mast cell progenitors. Stem Cells. 2010;28:2065-2072.","journal-title":"Stem Cells."},{"key":"6264_CR33","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.immuni.2018.09.023","volume":"49","author":"Z Li","year":"2018","unstructured":"Li Z, Liu S, Xu J, et al. Adult Connective Tissue-Resident Mast Cells Originate from Late Erythro-Myeloid Progenitors. Immunity. 2018;49:640-53.","journal-title":"Immunity."},{"key":"6264_CR34","first-page":"338","volume":"32","author":"N Ravanbakhsh","year":"2019","unstructured":"Ravanbakhsh N, Kesavan A. The role of mast cells in pediatric GI disease. Clin Rev Allergy Immunol. 2019;32:338-345.","journal-title":"Clin Rev Allergy Immunol."},{"key":"6264_CR35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12016-015-8487-6","volume":"54","author":"M Frieri","year":"2018","unstructured":"Frieri M. Mast cell activation syndrome. Clin Rev Allergy Immunol. 2018;54:353-365.","journal-title":"Clin Rev Allergy Immunol."},{"key":"6264_CR36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365520701245744","volume":"42","author":"GJ Molderings","year":"2007","unstructured":"Molderings GJ, Kolck UW, Scheurlen C, et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42:1045-1053.","journal-title":"Scand J Gastroenterol."},{"key":"6264_CR37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2014.09.001","volume":"93","author":"GJ Molderings","year":"2015","unstructured":"Molderings GJ. The genetic basis of mast cell activation disease - looking through a glass darkly. Crit Rev Oncol Hematol, 2015;93:75-89.","journal-title":"Crit Rev Oncol Hematol"},{"key":"6264_CR38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.14967","volume":"180","author":"RM Scherber","year":"2018","unstructured":"Scherber RM, Borate U. How we diagnose and treat systemic mastocytosis in adults. Brit J Haematol. 2018;180:11-23.","journal-title":"Brit J Haematol."},{"key":"6264_CR39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5858\/2006-130-362-MEIMMC","volume":"130","author":"S Jakate","year":"2006","unstructured":"Jakate S, Demeo M, John R, Tobin M, Keshavarzian A. Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 2006;130:362-367.","journal-title":"Arch Pathol Lab Med."},{"key":"6264_CR40","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","volume":"38","author":"LA Doyle","year":"2014","unstructured":"Doyle LA, Sepehr GJ, Hamilton MJ, et al. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38:832-843.","journal-title":"Am J Surg Pathol."},{"key":"6264_CR41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00418-018-1659-8","volume":"149","author":"D Atiakshin","year":"2018","unstructured":"Atiakshin D, Buchwalow I, Samoilova V, Tiemann M. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol. 2018;149:461-477.","journal-title":"Histochem Cell Biol."},{"key":"6264_CR42","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/nmo.12325","volume":"26","author":"H Lee","year":"2014","unstructured":"Lee H, Chung H, Park JC, et al. Heterogeneity of mucosal mast cell infiltration in subgroups of patients with esophageal chest pain. Neurogastroenterol Motil. 2014;26:786-793.","journal-title":"Neurogastroenterol Motil."},{"key":"6264_CR43","doi-asserted-by":"crossref","first-page":"29069","DOI":"10.3390\/ijms161226151","volume":"16","author":"A Aich","year":"2015","unstructured":"Aich A, Afrin LB, Gupta K. Mast cell-mediated mechanisms of nociception. Int J Molecular Sci. 2015;16:29069-29092.","journal-title":"Int J Molecular Sci."},{"key":"6264_CR44","first-page":"224689","volume":"2018","author":"LB Weinstock","year":"2018","unstructured":"Weinstock LB, Kaleem Z, Selby D, et al. Mast cell deposition and activation may be a new explanation for epiploic appendagitis. BMJ Case Rep. 2018;2018:bcr\u20132018\u2013224689.","journal-title":"BMJ Case Rep."},{"key":"6264_CR45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.gastro.2003.11.055","volume":"126","author":"G Barbara","year":"2004","unstructured":"Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126: 693-702.","journal-title":"Gastroenterology."},{"key":"6264_CR46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2006.11.039","volume":"132","author":"G Barbara","year":"2007","unstructured":"Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26-37.","journal-title":"Gastroenterology."},{"key":"6264_CR47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5056\/jnm15137","volume":"22","author":"L Zhang","year":"2016","unstructured":"Zhang L, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil. 2016;22:181-92.","journal-title":"J Neurogastroenterol Motil."},{"key":"6264_CR48","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/2050640617691690","volume":"5","author":"B Lobo","year":"2017","unstructured":"Lobo B, Ramos L, Mart\u00ednez C. Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterol J. 2017;5:887-897.","journal-title":"United European Gastroenterol J."},{"key":"6264_CR49","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gut.2010.213108","volume":"59","author":"TK Klooker","year":"2010","unstructured":"yKlooker TK, Braak B, Koopman KE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 201;59:1213-21.","journal-title":"Gut."},{"key":"6264_CR50","doi-asserted-by":"crossref","first-page":"G338","DOI":"10.1152\/ajpgi.00116.2018","volume":"316","author":"D Balemans","year":"2019","unstructured":"Balemans D, Aguilera-Lizarraga J, Florens MV, et al. Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2019;316:G338-9.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"6264_CR51","doi-asserted-by":"crossref","first-page":"ps670","DOI":"10.14309\/01.ajg.0000594304.61014.c5","volume":"114","author":"LW Weinstock","year":"2019","unstructured":"Weinstock LW, Rezaie R, Brook JB, et al. Small intestinal bacterial overgrowth is common in mast cell activation syndrome. Am J Gastroenterol. 2019;114:pS670.","journal-title":"Am J Gastroenterol."},{"key":"6264_CR52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2011.04684.x","volume":"34","author":"G Bassotti","year":"2011","unstructured":"Bassotti, G, Villanacci V, Nascimbeni R, et al. Colonic mast cells in controls and slow transit constipation patients. Aliment Pharmacol Ther. 2011;34:92-9.","journal-title":"Aliment Pharmacol Ther."},{"key":"6264_CR53","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.4049\/jimmunol.1000409","volume":"185","author":"I Shefler","year":"2010","unstructured":"Shefler I, Salamon P, Reshef T, Mor A, Mekori YA. T Cell-Induced Mast Cell Activation: A Role for Microparticles Released from Activated T Cells. J Immunol. 2010;185:4206-12.","journal-title":"J Immunol."},{"key":"6264_CR54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1478-3231.2008.01839.x","volume":"29","author":"K Alfter","year":"2009","unstructured":"Alfter K, K\u00fcgelgen Von I, Haenisch B, et al. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. 2009;29:181-6.","journal-title":"Liver Int."},{"key":"6264_CR55","first-page":"A489","volume":"28","author":"Z Rehman","year":"2018","unstructured":"Rehman Z, Rajumon M, Alam SB, et al. Prevalence and treatment of small intestinal bacterial overgrowth (SIBO) in patients with postural orthostatic tachycardia syndrome (POTS). Clin Auton Res. 2018;28:A489.","journal-title":"Clin Auton Res."},{"key":"6264_CR56","first-page":"221405","volume":"2018","author":"LB Weinstock","year":"2018","unstructured":"Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr\u20132017\u2013221405.","journal-title":"BMJ Case Rep."},{"key":"6264_CR57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/meta.2002.33187","volume":"51","author":"GE Plante","year":"2002","unstructured":"Plante GE. Vascular response to stress in health and disease. Metabol Clin Experiment. 2002;51:25-30.","journal-title":"Metabol Clin Exp."},{"key":"6264_CR58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajmg.c.31552","volume":"175","author":"F Malfait","year":"2017","unstructured":"Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8-26.","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"6264_CR59","first-page":"S270","volume":"113","author":"A Rezaie","year":"2018","unstructured":"Rezaie A, Raphaeal Y, Sukov R, Liu X. Ehlers-Danlos syndrome type III (EDS) and visceroptosis: getting to the bottom of this diagnosis. Am J Gastroenterolol. 2018;113:S270-1.","journal-title":"Am J Gastroenterolol."},{"key":"6264_CR60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1213\/XAA.0000000000000292","volume":"6","author":"LB Weinstock","year":"2016","unstructured":"Weinstock LB, Myers TL, Walters AS, et al. Identification and treatment of new inflammatory triggers for complex regional pain syndrome: small intestinal bacterial overgrowth and obstructive sleep apnea. A&A Case Reports. 2016;6:272-276.","journal-title":"A&A Case Rep."},{"key":"6264_CR61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajmg.c.31546","volume":"175","author":"A Fikree","year":"2017","unstructured":"Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:181-187.","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"6264_CR62","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.cgh.2014.01.014","volume":"12","author":"A Fikree","year":"2014","unstructured":"Fikree A, Grahame R, Aktar R, et al. A prospective evaluation of undiagnosed joint hypermobility syndrome in patients with gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2014;12:1680-1687.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"6264_CR63","doi-asserted-by":"crossref","first-page":"AB182","DOI":"10.1016\/j.jaci.2018.12.558","volume":"143","author":"AR Chang","year":"2019","unstructured":"Chang AR, Vadas P. Prevalence of Symptoms of Mast Cell Activation in Patients with Postural Orthostatic Tachycardia Syndrome and Hypermobile Ehlers-Danlos Syndrome. J Allergy Clin Immunol. 2019. AB182.","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"6264_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-8722-4-10","volume":"22","author":"GJ Molderings","year":"2011","unstructured":"Molderings GJ, Brettner S, Homann J, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011 Mar 22;4:10. doi: 10.1186\/1756-8722-4-10.","journal-title":"J Hematol Oncol."},{"key":"6264_CR65","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","volume":"48","author":"JJ Lyons","year":"2016","unstructured":"Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564-1569.","journal-title":"Nat Genet."},{"key":"6264_CR66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","volume":"180","author":"PA Valent","year":"2019","unstructured":"Valent PA, Bonadonna PB, Hartmann KC, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180:44-51.","journal-title":"Int Arch Allergy Immunol."},{"issue":"4","key":"6264_CR67","doi-asserted-by":"publisher","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","volume":"10","author":"M Vysniauskaite","year":"2015","unstructured":"Vysniauskaite M, Hertfelder H-J, Oldenburg J, et al. Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS One. 2015;10(4):e0124912. doi: 10.1371\/journal.pone.0124912.","journal-title":"PLoS One."},{"key":"6264_CR68","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","volume":"7","author":"M Castells","year":"2019","unstructured":"Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol Pract. 2019;7:1097-1106.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"6264_CR69","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","volume":"389","author":"GJ Molderings","year":"2016","unstructured":"Molderings GJ, Haenisch B, Brettner S, et al. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedebergs Arch Pharmacol. 2016;389:671-694.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol."},{"key":"6264_CR70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/gutjnl-2015-311339","volume":"66","author":"K McIntosh","year":"2017","unstructured":"McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66:1241-51.","journal-title":"Gut."},{"key":"6264_CR71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2019.10.037","volume":"158","author":"JBJ Kamphuis","year":"2020","unstructured":"Kamphuis JBJ, Guiard B, Leveque M, et al. Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Gastroenterology. 2020;158:652-63.","journal-title":"Gastroenterology."},{"key":"6264_CR72","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00210-013-0880-1","volume":"386","author":"AF Hagel","year":"2013","unstructured":"Hagel AF, Layritz CM, Hagel WH, et al. Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Naunyn-Schmiedebergs Arch Pharmacol. 2013;386:789-793.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol."},{"key":"6264_CR73","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1081-1206(10)61484-6","volume":"93","author":"TC Theoharides","year":"2004","unstructured":"Theoharides TC, Bielory L. Mast cells and mast cell mediators as targets of dietary supplements. Ann Allergy Asthma Immunol. 2004;93:S24-34.","journal-title":"Ann Allergy Asthma Immunol."},{"key":"6264_CR74","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/all.13110","volume":"72","author":"Z-Q Liu","year":"2017","unstructured":"Liu Z-Q, Li X-X, Qiu S-Q, et al. Vitamin D contributes to mast cell stabilization. Allergy. 2017; 72:1184-1192.","journal-title":"Allergy."},{"key":"6264_CR75","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18:693-704.","journal-title":"Nat Med."},{"key":"6264_CR76","doi-asserted-by":"publisher","unstructured":"Weinstock LB, Walters AS. Brook JB, Kaleem Z, Afrin LB, Molderings GJ. Restless legs syndrome is associated with mast cell activation syndrome. J Clin Sleep Med. 2020; https:\/\/doi.org\/10.5664\/jcsm.8216.","DOI":"10.5664\/jcsm.8216"},{"key":"6264_CR77","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1017\/S0033291709005601","volume":"39","author":"W Hamilton","year":"2009","unstructured":"Hamilton W, Gallagher A, Thomas J, White P. Risk markers for both chronic fatigue and irritable bowel syndromes: A prospective case-control study in primary care. Psychol Med. 2009;39:1913-21.","journal-title":"Psychol Med."},{"key":"6264_CR78","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1111\/j.1572-0241.1999.01643.x","volume":"94","author":"AD Sperber","year":"1999","unstructured":"Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3541-6.","journal-title":"Am J Gastroenterol."},{"key":"6264_CR79","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.juro.2010.06.005","volume":"184","author":"JC Nickel","year":"2010","unstructured":"Nickel JC, Tripp DA, Pontari M, et al. Interstitial cystitis\/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urology. 2010;184:1358\u201363.","journal-title":"J Urology."},{"key":"6264_CR80","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0090-4295(99)80469-5","volume":"47","author":"X Pang","year":"1996","unstructured":"Pang X, Boucher W, Triadafilopoulos G, Sant GR, Theoharides TC. Mast cell and substance p-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. Urology. 1996;47:436-8.","journal-title":"Urology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06264-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06264-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06264-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:25:16Z","timestamp":1619137516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06264-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6264"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06264-9","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"14 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs. Weinstock, Pace, Rezaie, and Afrin do not have any conflicts of interest. Dr. Molderings is the Chief Medical Officer of the startup company MC Sciences, Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}